http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm bone fractures bone fractures warns public warning bone fractures https://www.fda.gov/Drugs/DrugSafety/ucm461449.htm FDAのリリース post-marketing trial bone-weakening side effects Invokana and Invokamet bone fractures ósea (DMO) del antidiabético canaglifozina. warned http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm Drug Safety Communication – May 5, 2015 Bone fractures warnings http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm FDA Bone fractures http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm bone fractures Safety Communication www.fda.gov/Drugs/DrugSafety/ucm461449.htm http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm Safety Communication strengthened a warning might cause bone fractures bone fractures http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm new warnings September 2015 Safety Communication More information is available on FDA site Safety Communication http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm Invokana’s label already features a warning Drug Safety Communication – September 10, 2015 alert http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm